

## **Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. Adults**

Janeta Nikolovski, Ph.D., Martin Koldijk, B.Sc., Gerrit Jan Weverling, M.D., Ph.D., John Spertus, M.D., Mintu Turakhia, M.D., Leslie Saxon, M.D., Mike Gibson, M.D., John Whang, M.D., Troy Sarich, Ph.D., Bob Zambon, Ph.D., Nnamdi Ezeanochie, DrPH, Jennifer Turgiss, DrPH, Robyn Jones, M.D., Jeff Stoddard, M.D., Paul Burton, M.D., Ph.D., Ann Marie Navar, M.D., Ph.D.

### Affiliations

Nikolovski, Koldijk, Weverling, Whang, Sarich, Stoddard, Burton: **Janssen Pharmaceutical Companies of Johnson & Johnson**

Spertus: **University of Missouri Kansas City School of Medicine**

Turakhia: **Stanford University School of Medicine**

Saxon: **University of Southern California School of Medicine**

Gibson: **Harvard Medical School**

Ezeanochie, Turgiss, Jones: **Johnson & Johnson**

Navar: **UT Southwestern Medical Center**

### Corresponding Author

Ann Marie Navar, M.D., Ph.D.

Associate Professor of Medicine

UT Southwestern Medical Center

5323 Harry Hines Blvd 75390

Email: [ann.navar@UTsouthwestern.edu](mailto:ann.navar@UTsouthwestern.edu)

Phone 214-648-3111

## **ABSTRACT (248 WORDS)**

### **BACKGROUND**

The success of vaccination efforts to curb the COVID-19 pandemic will require broad public uptake of immunization and highlights the importance of understanding factors associated with willingness to receive a vaccine.

### **METHODS**

Adults enrolled in the Heartline™ clinical study were invited to complete a COVID-19 vaccine assessment through the Heartline™ mobile application between November 6-20, 2020. Factors associated with willingness to receive a COVID-19 vaccine were evaluated using an ordered logistic regression as well as a Random Forest classification algorithm.

### **RESULTS**

Among 9,106 study participants, 81.3% (n=7402) responded and had available demographic data. The majority (91.3%) reported a willingness to be vaccinated. Factors most strongly associated with vaccine willingness were beliefs about the safety and efficacy of COVID-19 vaccines and vaccines in general. Women and Black or African American respondents reported lower willingness to vaccinate. Among those less willing to get vaccinated, 66.2% said that they would talk with their health provider before making a decision. During the study, positive results from the first COVID-19 vaccine outcome study were released; vaccine willingness increased after this report.

### **CONCLUSIONS**

Even among older adults at high-risk for COVID-19 complications who are participating in a longitudinal clinical study, 1 in 11 reported lack of willingness to receive COVID-19 vaccine in November 2020. Variability in vaccine willingness by gender, race, education, and income suggests the potential for uneven vaccine uptake. Education by health providers directed toward

assuaging concerns about vaccine safety and efficacy can help improve vaccine acceptance among those less willing.

Clinicaltrials.gov NCT04276441

## **INTRODUCTION**

With the recent FDA Emergency Use Authorization (EUA) for two COVID-19 vaccines, significant attention is now being placed on whether sufficient numbers of the public will be willing to be immunized to control the pandemic and how to ensure the public is adequately informed about the vaccine.<sup>1,2,3</sup> Surveys in the United States showed an initial decline in reported willingness to receive a COVID-19 vaccine,<sup>4,5,6,7</sup> though more recent data appear more promising.<sup>5,8</sup>

Individual perceptions about vaccines and about COVID-19 can strongly influence the decision to vaccinate against COVID-19, and are likely more associated with vaccine behaviors than demographics alone.<sup>9,10,11</sup> Understanding these potentially modifiable factors are important to develop public health strategies to overcome vaccine hesitancy, especially among older and higher risk populations.<sup>12</sup>

Smartphone-based research can facilitate rapid data collection for timely research questions. To accelerate public health's understanding of current perspectives on vaccinations, we surveyed subjects already participating in a smartphone-based clinical trial, the Heartline™ Study, a virtual clinical study that is enrolling U.S. adults age 65 years and older. These participants are at high risk of COVID-19 related morbidity and mortality due to their age, and thus have a large potential benefit from immunization. In order to understand factors associated with and indicative of willingness to vaccinate in this higher risk population, we deployed a vaccine survey to all participants through the Heartline™ platform in November, 2020.

## **METHODS**

### **Study Population and Data Collection**

On February 25, 2020, enrollment began into The Heartline™ Study ([clinicaltrials.gov](https://clinicaltrials.gov), NCT04276441 and <https://heartline.com/>), a large heart health clinical study in the United States. Eligibility requirements include age 65 and older, possessing an iPhone 6s or later, current Original Medicare beneficiary, U.S. resident, and English-speaking (see [clinicaltrials.gov](https://clinicaltrials.gov), NCT04276441 for complete inclusion and exclusion criteria). The Heartline™ Study is investigating if wearable and custom-built mobile app technologies can enable earlier detection of atrial fibrillation (AF), reduce the incidence of clinical events, and improve adherence with oral anticoagulants in those with AF. The study is completely virtual, without the need for study site visits, and is conducted on the Heartline™ app. The study platform is designed to introduce novel surveys as needed throughout the study. The study protocol was approved by an IRB and all participants provide informed consent to analyze de-identified data, including surveys delivered through the Heartline™ app.

Willingness to vaccinate against COVID-19 was assessed through an optional survey through the Heartline™ app between November 6 and 20, 2020. The assessment was framed by the World Health Organization recommended Capability, Opportunity, Motivation and Behavior model (COM-B) model for addressing vaccine hesitancy and acceptance.<sup>13</sup> The assessment included questions regarding beliefs about vaccines in general, beliefs about COVID-19 and the COVID-19 vaccine, and opinions on vaccine dosing and potential side effects (see Supplement S1 for the complete assessment). The assessment was offered to all study participants. Demographic data were collected at the time of study enrollment, which included race and gender by self-report. The primary outcome of the study was self-reported willingness to receive a COVID-19 vaccine. This was captured on a four-point scale (very willing, somewhat willing, not very willing, not at all willing).

## Statistical Analysis and Model

To evaluate factors associated with vaccine willingness, we applied two different analytic approaches. First, determinants of willingness to be vaccinated were evaluated using an ordered univariate logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for race (Asian, Black or African American, White and other) and gender. Next, to identify a set of determinants to separate those who are willing to vaccinate from those who are not, recursive feature elimination in combination with a Random Forest classification algorithm<sup>15</sup> was performed. In this analysis, willingness to vaccinate was classified into two categories: willing to vaccinate (combining very willing with somewhat willing) and not willing to vaccinate (combining not at all willing with not very willing). The algorithm was trained using a dataset that was randomly split by stratum (either not willing or willing to be vaccinated), into a 2/3 training set (n=4935 with 91.3% willing to vaccinate) and a 1/3 different hold-out set to verify model performance (n=2467 with 91.3% willing to vaccinate).

For the machine learning models, categorical question and answer combinations from the survey and demographic variables, including gender, age, body mass index (BMI), race, income and education, were One-Hot encoded (i.e. converted to dummy variables). This resulted in a total of 85 features (Supplement S2) that were used for the construction of the Random Forest. The model was tuned with respect to terminal node size and mtry (number of features available for splitting at each tree node), with class imbalance being addressed using stratified re-sampling for each of the 4001 trees. The most relevant features were determined using a recursive feature elimination approach. Starting with a model trained using the complete set of features, normalized permutation importance scores were determined and the bottom 4% of features were

removed. The resulting model with all features (n=85) or the recursively reduced models were evaluated using the hold-out dataset. The model with the minimum set of features was selected based on maintaining a high balanced accuracy on the hold-out dataset (i.e., the average of specificity and sensitivity), compared to the full model.

Shortly after the November survey was offered, Pfizer announced a first interim analysis reporting >90% efficacy of their vaccine candidate on November 9, 2020.<sup>14</sup> We investigated if that news had an impact on willingness to vaccinate in our population and compared those who answered the survey before the 9<sup>th</sup> to those who answered after (excluding those who answered on the 9<sup>th</sup> itself) using an ordered logistic regression model with four-level willingness to be vaccinated as the outcome and an indicator variable for the time period (before and after November 9<sup>th</sup>) and gender as predictors. Statistical analyses were performed using *R* (3.5.1 and 3.6.1) and r-packages *randomForest* (4.6-14)<sup>15</sup>, *caret* (6.0-84)<sup>16</sup> and *MASS* (7.3-53).<sup>17</sup>

Data analyses was performed by JN, MK and GJW.

## RESULTS

### Willingness to vaccinate against COVID-19

The assessment was offered to 9,106 participants with 7,621 (83.6%) completing the survey. Excluding participants (n=219) missing demographic data left 7,402 participants (81.3%) for the study analyses (Table 1). Overall, 63.6% of participants reported they were very willing to receive a COVID-19 vaccine, 27.8% were somewhat willing, 6.0% were not very willing, and 2.6% were not at all willing. Treated as a dichotomous response, 91.3% were considered “willing” to be immunized while 8.7% were “unwilling” (Table 1).

Figure 1 shows results of univariable evaluations of demographic factors associated with vaccine willingness. Black or African American race was most strongly associated with decreased odds of vaccine willingness (odds ratio 0.24, 95% CI 0.18 – 0.31) (Figure 1). A total of 26.8% of Black or African American participants noted they were not very willing or not at all willing to vaccinate, compared with 8.0% of white participants (Table 1). Women were also less willing to be vaccinated as shown in Table 1 by 12.1 % of women and 5.7% of men being not very or not at all willing to vaccinate against COVID-19 (odds ratio 0.49, 95% CI 0.45 – 0.54) (Figure 1). Income and education are also associated with willingness to be vaccinated, with higher income and higher education being associated with a higher willingness to be vaccinated (Figure 1).

Surveyed beliefs about COVID-19 and the COVID-19 vaccine (Figure 2), as well as beliefs about vaccines in general (Supplemental S3), were found to be strongly associated with willingness to vaccinate. Regarding COVID-19, the most strongly associated beliefs included that the COVID-19 vaccine will help protect “myself and others” (odds ratio 38.6, 95% CI 32.4 – 46.1), the COVID-19 vaccine would be safe and effective (odds ratio 21.6, 95% CI 18.9 – 24.7), and being comfortable with short term side effects such as prolonged injection site pain (odds ratio 10.9, 95% CI 9.1 – 13.1). These beliefs were consistently important across participants who were White, Asian, African American or Black (Supplemental S4).

### **Information seeking**

The vast majority of those who would be willing to vaccinate indicated they would talk to their healthcare provider (HCP) or staff before deciding whether or not to receive the vaccine (91.4% of women and 88.9% of men) (Supplement S5). The majority of those who indicated

they would not be willing to be vaccinated (68.4% of women and 62.3% of men) also indicated they would talk to their healthcare provider before deciding (Supplement S5).

Specifically, we categorized the proportions of those who would talk to their HCP before deciding among those not at all willing and not very willing, by gender and race (Table 2). Of those not very willing, greater than 75% would talk to their HCP first (75.0% White, N=376; 85.3% Black or African American, N=34). Even among those not at all willing to vaccinate, around half would talk to their HCP before deciding (48.2% White, N=168; 53.3% Black or African American, N=15).

### **Participant characteristics and beliefs indicative of vaccine willingness**

To identify a set of determinants that separate those who are willing and unwilling to be vaccinated, we constructed a Random Forest classification algorithm. From the survey and the available self-reported demographic data, we extracted a list of features (Supplemental S2, S5) to be used in the first model. This initial model using all 85 features resulted in 90.2% balanced accuracy (average of 90.7% sensitivity and 89.7% specificity) when applied to the hold-out dataset. When testing the recursively reduced models, the balanced accuracy remained near constant up to the model with 9 remaining features (89.5% balanced accuracy with 87.4% sensitivity and 91.6% specificity). A further reduction (removing the least important feature from the set of 9) resulted in a 12.3 percent point reduction in balanced accuracy primarily due to misclassification of the not willing to vaccinate (Specificity = 55.6%).

The features coming out of our model (Figure 3) revealed five main indicators: belief whether the COVID-19 vaccine would be safe and effective, belief whether a COVID-19 vaccine would help protect “myself and others,” degree of comfort with potential short term side effects

from a COVID-19 vaccine, the belief whether vaccines in general are safe and important, and whether the respondent was Black or African American.

### **Impact of positive vaccine news**

Willingness to vaccinate increased after November 9<sup>th</sup> when results of the Pfizer phase 3 vaccine trial were released (odds ratio 1.46, 95% CI 1.28 – 1.69, Supplemental S6). Prior to that date, 2.8% of adults were not at all willing to receive a COVID-19 vaccine and 6.4% were “not very” willing; after this these decreased to 1.7% and 5.7%, respectively.

## **DISCUSSION**

The recent approval of vaccines for COVID-19 has increased the focus on the need to maximize public vaccine acceptance. Vaccine uptake in older adults is of particular importance as increasing age is the leading risk factor for mortality and complications from COVID-19 infections.<sup>12</sup> In this large survey of adults age 65 and older conducted in the United States in November 2020, the vast majority (91%) of adults reported that they are willing to receive a COVID-19 vaccine. However, even in this population of people with sufficient health literacy and trust in the healthcare system to participate in a digital clinical trial, 1 in 11 reported unwillingness to receive a vaccine. More concerning, rates of vaccine unwillingness were higher in Black or African American adults and those at lower income and education levels, suggesting the potential for uneven vaccine uptake in at-risk communities.

In this study, Black or African American race was the only factor associated with willingness to immunize after accounting for beliefs about the vaccine; 1 in 4 Black or African American participants reported unwillingness to receive a vaccine. This is slightly lower than

previous reports of ~40% unwilling,<sup>8,19,20</sup> but is consistent with other studies that show that willingness among Black or African Americans is improving.<sup>7</sup> We also found lower rates of reported vaccine willingness in women compared with men, a factor that has been shown in other studies.<sup>11,19</sup> Socioeconomic factors, including higher education and higher income, were also associated with increased reported willingness to be vaccinated. Notably, these findings contrast with characteristics of adults who refuse vaccines for their children. In studies of vaccine exemptions, higher income and education are often associated with higher rates of vaccine refusal.<sup>18</sup> Given that lower income communities and communities of color are at higher risk of COVID-19, vaccine hesitancy in these groups is of particular concern. Even if overall vaccine uptake is high, clustering of unimmunized persons can lead to continued circulation of vaccine-preventable diseases.<sup>21</sup>

The strongest factors associated with and indicative of vaccine willingness in this population were beliefs about the COVID-19 vaccine's safety and efficacy, and a more altruistic belief whether a COVID-19 vaccine will help protect "myself and others." Among those disinclined to vaccinate, the majority stated that they would discuss their decision with their healthcare provider, providing an important opportunity for education. Despite differences in rates of vaccine willingness by gender and race, the associations between beliefs about a COVID-19 vaccine and reported willingness to receive a vaccine were consistent across subgroups. In addition to broader public education campaigns about COVID-19, specific efforts should be made to facilitate healthcare patient-provider communication about COVID-19 vaccine focused on vaccine safety and efficacy.

While the study was not designed to determine the impact of vaccine-related news, the release of results from Pfizer's Phase 3 vaccine trial occurring in the middle of the survey

provided an opportunity to evaluate the impact of positive vaccine news on vaccine attitudes. Increased vaccine willingness was seen after the trial results were released, suggesting that public willingness to vaccinate may continue to rise as additional positive data are released. On the other hand, given the potential for vaccine related data to shift perception, there remains the possibility that negative news stories about the vaccine (including reports of adverse events) may negatively impact vaccine willingness.

The high willingness among participants in our population to be vaccinated is similar to that reported in other assessments in this age group. Recently reported results from the Kaiser Family Foundation found that 85% of those 65 and older were willing to receive a vaccine.<sup>8</sup> Older adults consistently express a higher willingness to accept a COVID-19 vaccine than younger populations.<sup>3,5,6,11</sup> Reasons for this may include a higher perceived risk of COVID-19 illness compared to younger adults, prior experience with vaccine preventable diseases and mass vaccination campaigns for diseases such as polio, or comfort with routine immunizations due to being recommended for influenza vaccine.

This study demonstrates the power of the digital platform used in the Heartline<sup>TM</sup> Study to rapidly generate real-world data. There are key features of this platform that enable rapid data generation: a properly constructed informed consent form that permits ad hoc survey deployment for data collection; a mobile app capable of pushing content and gathering variable but structured data; a back-end data structure that enables rapid analysis; and an app design that keeps participants highly engaged throughout the entire study, as evidenced by 83.6% of participants who took the survey. This platform opens the possibility of studies that investigate multiple effects over time or serial interventions in a population.

These findings should be interpreted in the context of several potential limitations. There is an inherent bias that comes with studying populations who have chosen to enroll into a clinical study. Heartline™ participants have less representation of Black or African American and Asians compared to the general U.S. 65+ population and skew higher in education and income, which may have led to an overestimate of vaccine acceptance compared with the general population. Nevertheless, finding that 1 in 11 patients in this selected group are unwilling to be vaccinated may portend even lower rates in a broader population. Next, our analysis of the impact of vaccine-related news occurred during a time period when infections continued to rise; whether changes in attitudes were due to vaccine news or due to other factors is unclear. Finally, we asked about vaccine willingness, which may not directly translate into behavior, particularly if attitudes shift over time. We also highlight several strengths, including a high response rate (>80%), a short period of data collection (2 weeks), and the ability to deploy the survey rapidly in response to the pandemic.

In a 65 and older U.S. population, most are willing to be vaccinated, with Black or African American participants and females significantly less willing. The majority would be willing to discuss their concerns with their providers, who could leverage the beliefs identified here in tailoring a message to encourage vaccination. Developing implementable strategies to consistently communicate the potential benefits of vaccination could improve acceptance and help speed the efforts to thwart this global pandemic.

The Heartline™ Study is supported by Johnson & Johnson and Apple. Apple neither supported nor participated in survey development or interpretation for this article.

## REFERENCES

1. Bloom BR, Nowak GJ and Orenstein W. “When will we have a vaccine?” – Understanding questions and answers about Covid-19 vaccination. *N Engl J Med* 2020; 383:2202-2204.  
DOI: 10.1056/NEJMp2025331
2. Schiavo R. (2020) Vaccine communication in the age of COVID-19: Getting ready for an information war, *J Healthc Commun* 2020;13:2,73-75.  
DOI: 10.1080/17538068.2020.1778959
3. Cornwall W. Just 50% of Americans plan to get a Covid-19 vaccine. Here’s how to win over the rest. *Science*. June 30, 2020 (<https://www.sciencemag.org/news/2020/06/just-50-americans-plan-get-covid-19-vaccine-here-s-how-win-over-rest>).
4. Silverman E. STAT-Harris Poll: The share of Americans interested in getting COVID-19 vaccine as soon as possible is dropping. *STAT*. October 19, 2020 (<https://www.statnews.com/pharmalot/2020/10/19/covid19-coronavirus-pandemic-vaccine-racial-disparities/>).
5. Reinhart RJ. More Americans now willing to get COVID-19 vaccine. *Gallup*. November 17, 2020 (<https://news.gallup.com/poll/325208/americans-willing-covid-vaccine.aspx>).
6. Lazarus JV, Ratzan SC, Palayew A, *et al.* A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* 2020. DOI:10.1038/s41591-020-1124-9
7. Talev M. Axios-Ipsos poll: Vaccine resistance grows. *Axios*. September 22, 2020 ([https://www.axios.com/axios-ipsos-poll-coronavirus-index-vaccine-doubts-e9205f29-8c18-4980-b920-a25b81eebd84.html?mkt\\_tok=eyJpIjoiTm1Wak56QTBaVGxrTmpGaSIsInQiOiJ3WXdscTJ2NmVGOEpmeUpZdXdXOEIZRnR1Umptd3ZkUEpCRzRNUWdYbm5Wa29pOVdMNkxr](https://www.axios.com/axios-ipsos-poll-coronavirus-index-vaccine-doubts-e9205f29-8c18-4980-b920-a25b81eebd84.html?mkt_tok=eyJpIjoiTm1Wak56QTBaVGxrTmpGaSIsInQiOiJ3WXdscTJ2NmVGOEpmeUpZdXdXOEIZRnR1Umptd3ZkUEpCRzRNUWdYbm5Wa29pOVdMNkxr)

[TkpGSndmVUpFem5Senl4OGg4a1NVMWdSdXY1MFJuZXNrSzlySysrN1jQStqcWJkZ1FGR1dyR0VfVHJQazQzTUZ0em9rOTRcL2liaFMifQ%3D%3D](https://doi.org/10.1101/2021.01.10.20248831)

8. Hamel L, Kirzinger A, Munana C, and Brodie M. KFF COVID-19 vaccine monitor: December 2020 (<https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/>).
9. Rothwell J. New experiment shows how to boost COVID-19 vaccine acceptance. Gallup. October 30, 2020 (<https://news.gallup.com/poll/323378/new-experiment-shows-boost-covid-vaccine-acceptance.aspx>).
10. Kreps S, Prasad S, Brownstein JS, *et al.* Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw Open.* 2020;3(10):e2025594.  
DOI:10.1001/jamanetworkopen.2020.25594
11. Malek AA, McFadden SM, Elharake J, and Omer SB. Determinants of COVID-19 vaccine acceptance in the U.S. *EClinicalMedicine* 2020;26,100495.  
DOI:10.1016/j.eclinm.2020.100495
12. Kang S and Jung SI. Age-related morbidity and mortality among patients with COVID-19. *Infect Chemother.* 2020;Jun;52(2):154-164. DOI:10.3947/ic.2020.52.2.154
13. Michie, S, van Stralen, MM, and West, R. The behavior change wheel: a new method for characterizing and designing behavior change interventions. *Implement. Sci.* 2011;6,42.
14. Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study. November 9, 2020.  
<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against>

15. Liaw A and Wiener M Classification and Regression by randomForest. R News 2002;2(3), 18—22.
16. Kuhn M. Contributions from Jed Wing, Steve Weston, Andre Williams, Chris Keefer, Allan Engelhardt, Tony Cooper, Zachary Mayer, Brenton Kenkel, the R Core Team, Michael Benesty, Reynald Lescarbeau, Andrew Ziem, Luca Scrucca, Yuan Tang, Can Candan and Tyler Hunt. (2019). caret: Classification and Regression Training. R package version 6.0-84. <https://CRAN.R-project.org/package=caret>
17. Venables, WN and Ripley, BD, eds. Modern Applied Statistics with S. 4<sup>th</sup> ed. Springer, New York. 2002. ISBN 0-387-95457-0
18. Wei F, Mullooly JP, Goodman M, McCarty MC et al. Identification and characteristics of vaccine refusers. BMC Pediatr 2009;9,18. DOI:10.1186/1471-2431-9-18
19. Wan W. Coronavirus vaccine face trust gap in Black and Latino communities, study finds. The Washington Post. November 3, 2020 [\(https://www.washingtonpost.com/health/2020/11/23/covid-vaccine-hesitancy/\)](https://www.washingtonpost.com/health/2020/11/23/covid-vaccine-hesitancy/).
20. Warren RC, Forrow L, Hodge DA, and Truong RD. Trustworthiness before Trust – Covid-19 Vaccine Trials and the Black Community. N Engl J Med 2020; 383:e121 DOI: 10.1056/NEJMp2030033
21. Omer SB, Enger KS, Moulton LH, Halsey NA, Stokley S, Salmon DA. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol 2008; Dec 15;168(12):1389-96. DOI: 10.1093/aje/kwn263

## TABLE AND FIGURE LEGENDS

### **Table 1. Demographics of the participants completing the vaccine assessment overall and stratified by vaccine willingness**

Plus-minus values are means  $\pm$  standard deviations (SD). Overall column percentages represent % of overall sample (column percent). Percentages in willing and unwilling columns represent row %.

† The body-mass index is the weight in kilograms divided by the square of the height in meters.

‡ Race was reported by the participants, who could select more than one category.

### **Figure 1: Forest plot of willingness to vaccinate by demographics**

Shown are Odds Ratios (95% CI) for willingness to vaccinate for the different demographic characteristics. Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race.

Reference for each category is indicated by an open circle. *na* indicate not sufficient subjects for this category. ‘Native Hawaiian or Other Pacific Islander’, ‘Two or more’, and ‘Prefer not to answer’ are combined in ‘Other’.

### **Figure 2: Forest plot of willingness to vaccinate by survey response**

Shown are Odds Ratios (95% CI) for willingness to vaccinate for the different demographic characteristics. Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race.

Reference for each survey question is the option ‘neutral’ and is indicated by an open circle. For example subjects who agreed with the question ‘*I am comfortable taking a COVID-19 vaccine that has*

short term side effects such as stomach pain or nausea if the vaccine efficiently prevents COVID-19.' are 3.0 times more likely to be more willing as compared to those who selected 'neutral'

### **Figure 3: Result of recursive feature elimination algorithms**

Random Forest classification algorithm was constructed to identify a set of determinants able to separate those who are not willing to vaccinate from those who are. The model started with a list of 85 features and predicted the willingness of subjects in the hold-out dataset with 90.2% balanced accuracy (solid line), which is an average of 90.7% sensitivity (dashed line closed circles) and 89.7% specificity(dashed line open circles). The balanced accuracy remained near constant when testing the recursively reduced models, up to the model with 9 remaining features (i.e. 5 questions with a total of 9 answers, see inserted table). This final model showed an 89.5% balanced accuracy with 87.4% sensitivity and 91.6% specificity. Further reduction, removing the least important feature from the set of 9 (i.e. 'Neutral' to '*Once approved, I believe a COVI-19 vaccine will help protect myself and others*'), resulted in a 12.3 percent point reduction in balanced accuracy primarily due to misclassification of the not willing to vaccinate (Specificity = 55.6%).

### **Table 2: Talking to Healthcare provider within levels of willing to vaccinate**

An overview of those who would talk to their Healthcare Provider among the 4 levels of willingness, by race and gender. Note: due to small numbers, Native Hawaiian or Other Pacific Islander (n=8), American Indian or Alaska Native (n=21), Two or more (n=44) and Prefer not to Answer (n=114) were excluded from the table.

**Table 1. Demographics of the participants completing the vaccine assessment**


		Total	Unwilling to Receive Vaccine	Willing to Receive Vaccine
Subjects (N, %)		7402 (100%)	642 (8.7%)	6760 (91.3%)
Gender (N, %)	Women	3423 (46.2%)	414 (12.1%)	3009 (87.9%)
	Men	3979 (53.8%)	228 (5.7%)	3751 (94.3%)
Age (yr, mean ± SD)		70.8 ± 4.7	70.2 ± 4.4	70.9 ± 4.8
Age (N, %)	[65,70)	3509 (47.4%)	329 (9.4%)	3180 (90.6%)
	[70,75)	2378 (32.1%)	216 (9.1%)	2162 (90.9%)
	[75,80)	1093 (14.8%)	73 (6.7%)	1020 (93.3%)
	[80,85)	337 (4.6%)	18 (5.3%)	319 (94.7%)
	[85,90)	71 (1.0%)	6 (8.5%)	65 (91.5%)
	[90,95)	12 (0.2%)	0 (0.0%)	12 (100%)
	[95,100)	2 (0.0%)	0 (0.0%)	2 (100%)
BMI (kg/m <sup>2</sup> , mean ± SD) †		27.5 ± 5.3	27.9 ± 5.6	27.4 ± 5.3
BMI (N, %)	Under weight (<18.5)	90 (1.2%)	4 (4.4%)	86 (95.6%)
	Normal weight (18.5 - 25)	2525 (34.1%)	209 (8.3%)	2316 (91.7%)
	Overweight (25.0 - 30)	2850 (38.5%)	229 (8.0%)	2621 (92.0%)
	Obese (>= 30)	1937 (26.2%)	200 (10.3%)	1737 (89.7%)
Race (N, %) ‡	American Indian or Alaska Native	21 (0.3%)	1 (4.8%)	20 (95.2%)
	Asian	238 (3.2%)	21 (8.8%)	217 (91.2%)
	Black or African American	183 (2.5%)	49 (26.8%)	134 (73.2%)
	Native Hawaiian or Other Pacific Islander	8 (0.1%)	3 (37.5%)	5 (62.5%)
	Two or more	44 (0.6%)	3 (6.8%)	41 (93.2%)
	White	6794 (91.8%)	544 (8.0%)	6250 (92.0%)
	Prefer not to answer	114 (1.5%)	21 (18.4%)	93 (81.6%)
Education (N, %)	Some high school or less	18 (0.2%)	3 (16.7%)	15 (83.3%)
	High school diploma or equivalent (GED)	280 (3.8%)	41 (14.6%)	239 (85.4%)
	Some college education	1104 (14.9%)	152 (13.8%)	952 (86.2%)
	Associate degree (e.g. AA, AS)	509 (6.9%)	66 (13.0%)	443 (87.0%)

	Bachelor's degree (e.g. BA, BS)	2285 (30.9%)	173 (7.6%)	2112 (92.4%)
	Master's degree (e.g. MA, MS, MEd)	2179 (29.4%)	148 (6.8%)	2031 (93.2%)
	Doctorate (e.g. PhD, EdD)	480 (6.5%)	29 (6.0%)	451 (94.0%)
	Professional degree (e.g. MD, DDS, DVM)	499 (6.7%)	23 (4.6%)	476 (95.4%)
	Prefer not to answer	48 (0.6%)	7 (14.6%)	41 (85.4%)
Income (N, %)	Under \$30,000	356 (4.8%)	56 (15.7%)	300 (84.3%)
	\$30,000-\$39,999	308 (4.2%)	43 (14.0%)	265 (86.0%)
	\$40,000-\$49,999	343 (4.6%)	55 (16.0%)	288 (84.0%)
	\$50,000-\$59,999	442 (6.0%)	45 (10.2%)	397 (89.8%)
	\$60,000-\$74,999	747 (10.1%)	79 (10.6%)	668 (89.4%)
	\$75,000-\$99,999	1115 (15.1%)	78 (7.0%)	1037 (93.0%)
	\$100,000-\$149,999	1485 (20.1%)	85 (5.7%)	1400 (94.3%)
	\$150,000-\$200,000	688 (9.3%)	30 (4.4%)	658 (95.6%)
	Above \$200,000	632 (8.5%)	26 (4.1%)	606 (95.9%)
	Prefer not to answer	1286 (17.4%)	145 (11.3%)	1141 (88.7%)


† The body-mass index is the weight in kilograms divided by the square of the height in meters.

‡ Race was reported by the participants, who could select more than one category.


**Figure 1: Forest plot of willingness to vaccinate by demographics**



**Figure 2: Forest plot of willingness to vaccinate by survey response**



**Figure 3: Result of recursive feature elimination algorithms**



**Table 2: Talking to Healthcare provider within levels of willing to vaccinate**

I would talk to my healthcare provider when considering a COVID-19 vaccine, before deciding whether or not to receive the vaccine.						
Race	Gender	Variable	Not at all willing	Not very willing	Somewhat willing	Very willing
Asian	Women	Talk with HCP (No)	0 (0.0%)	5 (45.5%)	9 (22.0%)	1 (2.0%)
		Talk with HCP (Yes)	1 (100%)	6 (54.5%)	32 (78.0%)	48 (98.0%)
	Men	Talk with HCP (No)	3 (100%)	5 (83.3%)	7 (18.9%)	17 (18.9%)
		Talk with HCP (Yes)	0 (0.0%)	1 (16.7%)	30 (81.1%)	73 (81.1%)
Black or African American	Women	Talk with HCP (No)	6 (46.2%)	2 (9.1%)	2 (4.2%)	1 (3.6%)
		Talk with HCP (Yes)	7 (53.8%)	20 (90.9%)	46 (95.8%)	27 (96.4%)
	Men	Talk with HCP (No)	1 (50.0%)	3 (25.0%)	2 (5.7%)	3 (13.0%)
		Talk with HCP (Yes)	1 (50.0%)	9 (75.0%)	33 (94.3%)	20 (87.0%)
White	Women	Talk with HCP (No)	56 (48.7%)	56 (23.8%)	83 (8.2%)	157 (9.0%)
		Talk with HCP (Yes)	59 (51.3%)	179 (76.2%)	930 (91.8%)	1596 (91.0%)
	Men	Talk with HCP (No)	31 (58.5%)	38 (27.0%)	72 (8.7%)	299 (11.3%)
		Talk with HCP (Yes)	22 (41.5%)	103 (73.0%)	755 (91.3%)	2358 (88.7%)

## SUPPLEMENTARY MATERIALS

### **S1: Vaccine Hesitancy Assessment**

#### **Table S2: Recursive feature elimination algorithm feature definitions**

#### **Figure S3: Forest plot of willingness to vaccinate by survey response (general vaccine beliefs)**

Shown are Odds Ratios (95% CI) for willingness to vaccinate. Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race.

#### **Figure S4: Forest plots of willingness to vaccinate by COVID-19 beliefs and race**

Shown are Odds Ratios (95% CI) for willingness to vaccinate for the survey by race: White (A), Asian (B), and Black (C). Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race. Reference for each survey question is the option 'neutral' and is indicated by an open circle. *na* indicates insufficient subjects for this category.

#### **Table S5: Willingness to be vaccinated by Model features from survey**

#### **Table S6: Impact of positive vaccine efficacy news by level of willing to vaccinate**

November 9, 2020, Pfizer announced a first interim analysis reporting >90% efficacy of their vaccine candidate. The impact of this news on willingness was evaluated among those who answered the survey before the 9th to those who answered thereafter (excluding those who answered on the 9th itself). Those after November 9th were more willing to vaccinate (odds ratio 1.46, 95%CI 1.28 – 1.69).

## S1: Vaccine Hesitancy Assessment

### Beliefs about vaccines

1. **In your opinion, how important are vaccines in general?** Very important; Somewhat important; Not very important; Not important at all
2. **In your opinion, how safe are vaccines in general?** Very safe; Somewhat safe; Not very safe; Not at all safe
3. **Which of the following statements are true about your experience with vaccines in general?** (*Select all that apply*) I have not had a problem after receiving a vaccine; The side effects of vaccines are generally manageable; I am concerned about the short-term side effects; I am concerned about the long-term side effects; I have a fear of vaccines or needles; I feel that I may be putting myself at risk by receiving a vaccine; None of the above (*exclusive*)
4. **Which of the following statements are true about your knowledge of vaccines in general?** (*Select all that apply*) I believe I have enough information about vaccines; I believe they are safe and effective; I believe the vaccine approval process is highly and well regulated; I do not have enough information about vaccines; I do not believe they are safe and effective; I saw or heard negative news about vaccines; None of the above (*exclusive*)

### Willingness to be vaccinated for COVID-19

1. **Has the COVID-19 pandemic made you more likely to vaccinate, in general, as compared to pre-pandemic times?** Much more likely; Somewhat more likely; Just as likely; Somewhat less likely; Much less likely
2. **When considering a COVID-19 vaccine, which of the following people (if any) would you talk to before deciding whether or not to receive the vaccine?** (*Select all that apply*) My pharmacist; My healthcare provider or their staff; My friends or family; My significant other or partner; Religious leaders; Community leaders; Trusted online forums or sites; None of the above (*exclusive*)
3. **Where would you look to for information to help you decide whether or not to receive a COVID-19 vaccine?** (*Select all that apply*) Online searches (Google, the vaccine manufacturers website, etc.); Clinicaltrials.gov; My healthcare provider's office; Information from a patient support or advocacy group; Social media or other online forums ; None of the above (*exclusive*)
4. **Once available to the public, how willing would you be to receive a vaccine to protect you against COVID-19?** Very willing; Somewhat willing; Not very willing; Not at all willing
5. **If you were to receive a COVID-19 vaccine, where would you prefer to have it administered?** (*Select all that apply*) Not applicable (*exclusive*); Healthcare provider's office; Hospital; Pharmacy (e.g., Walgreens, CVS, other); Workplace; Community health clinic; Religious centers; A mobile health unit (e.g., van or health tent)
6. **COVID-19 is highly contagious.** Agree; Neutral; Disagree
7. **COVID-19 is highly severe.** Agree; Neutral; Disagree
8. **I believe I am at risk of getting COVID-19.** Agree; Neutral; Disagree
9. **Once approved, I believe a COVID-19 vaccine would be safe and effective.** Agree; Neutral; Disagree

10. **Once approved, I believe a COVID-19 vaccine will help protect myself and others.** Agree; Neutral; Disagree
11. **I prefer my healthcare provider recommend that I receive a COVID-19 vaccine before I receive it.** Agree; Neutral; Disagree
12. **I prefer my family or social network also receive a COVID-19 vaccine before I receive it.** Agree; Neutral; Disagree
13. **I need more information about a COVID-19 vaccine's safety and efficacy.** Agree; Neutral; Disagree
14. **I am concerned a COVID-19 vaccine will have side effects.** Agree; Neutral; Disagree
15. **I am concerned my insurance will not cover a COVID-19 vaccine.** Agree; Neutral; Disagree
16. **I am concerned about receiving a COVID-19 vaccine because I'm afraid of needles.** Agree; Neutral; Disagree
17. **If a COVID-19 vaccine requires two doses, I believe that taking the first dose will sufficiently reduce my risk of contracting COVID-19.** Agree; Neutral; Disagree
18. **If a COVID-19 vaccine requires two doses, I believe that taking both doses will reduce my risk of contracting COVID-19.** Agree; Neutral; Disagree
19. **I am comfortable taking a COVID-19 vaccine that has short term side effects such as prolonged injection site pain (e.g., redness or swelling) if the vaccine efficiently prevents COVID-19.** Agree; Neutral; Disagree
20. **I am comfortable taking a COVID-19 vaccine that has short term side effects such as moderate fever (>38 degrees Celsius or > 100 degrees Fahrenheit) if the vaccine efficiently prevents COVID-19.** Agree; Neutral; Disagree
21. **I am comfortable taking a COVID-19 vaccine that has short term side effects such as stomach pain or nausea if the vaccine efficiently prevents COVID-19.** Agree; Neutral; Disagree


**Table S2: Recursive feature elimination algorithm feature definitions**

Variable	Levels	Features (n)
Gender	1=Man, 0=Woman	1
Age	[65,70), [70,75), [75,80), [80,85) [85,90), [90,95), [95,100)	7
BMI	Under weight (<18.5), Normal weight (18.5 - 25), Overweight (25.0 - 30), Obese (>= 30)	4
Race	American Indian or Alaska Native, Asian Black or African American, Native Hawaiian or Other Pacific Islander, White, Prefer not to answer / Two or more	6
Education	Some high school or less, High school diploma or equivalent (GED), Some college education, Associate degree (e.g. AA, AS), Bachelor's degree (e.g. BA, BS) Master's degree (e.g. MA, MS, MEd), Doctorate (e.g. PhD, EdD), Professional degree (e.g. MD, DDS, DVM), Prefer not to answer	9
Income	Under \$30,000, \$30,000-\$39,999, \$40,000-\$49,999, \$50,000-\$59,999, \$60,000-\$74,999, \$75,000-\$99,999, \$100,000-\$149,999, \$150,000-\$200,000, Above \$200,000, Prefer not to answer	10
In your opinion, how safe are vaccines in general?	Not at all safe, Not very safe, Somewhat safe, Very safe	4
Once available to the public, how willing would you be to receive a vaccine to protect you against COVID-19?	Not at all willing, Not very willing, Somewhat willing, Very Willing	4
COVID-19 is highly contagious.	Disagree, Neutral, Agree	3
COVID-19 is highly severe.	Disagree, Neutral, Agree	3
I believe I am at risk of getting COVID-19.	Disagree, Neutral, Agree	3
Once approved, I believe a COVID-19 vaccine would be safe and effective.	Disagree, Neutral, Agree	3
Once approved, I believe a COVID-19 vaccine will help protect myself and others.	Disagree, Neutral, Agree	3
I need more information about a COVID-19 vaccine's safety and efficacy.	Disagree, Neutral, Agree	3
I am concerned a COVID-19 vaccine will have side effects.	Disagree, Neutral, Agree	3
I am concerned my insurance will not cover a COVID-19 vaccine.	Disagree, Neutral, Agree	3
I am concerned about receiving a COVID-19 vaccine because I am afraid of needles	Disagree, Neutral, Agree	3
I am comfortable taking a COVID-19 vaccine that has short term side effects such as prolonged injection site pain (e.g., redness or swelling) if the vaccine efficiently prevents COVID-19.	Disagree, Neutral, Agree	3
I am comfortable taking a COVID-19 vaccine that has short term side effects such as moderate fever (>38 degrees celsius or > 100 degrees Fahrenheit) if the vaccine efficiently prevents COVID-19.	Disagree, Neutral, Agree	3
I am comfortable taking a COVID-19 vaccine that has short term side effects such as stomach pain or nausea if the vaccine efficiently prevents COVID-19.	Disagree, Neutral, Agree	3
I would talk to my healthcare provider when considering a COVID-19 vaccine, before deciding whether or not to receive the vaccine.	1 = Yes, 0=No	1
I would talk to none of the above when considering a COVID-19 vaccine, before deciding whether or not to receive the vaccine.	1 = Yes, 0=No	1
I would do online searches (Google, the vaccine manufacturers website, etc) to help me decide whether or not to receive a COVID-19 vaccine.	1 = Yes, 0=No	1
I would do not look for information to help me decide whether or not to receive a COVID-19 vaccine	1 = Yes, 0=No	1
	Total	85


**Figure S3: Forest plot of willingness to vaccinate by survey response (general vaccine beliefs)**

Shown are Odds Ratios (95% CI) for willingness to vaccinate. Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race.

**A**




**B**




**Figure S4: Forest plots of willingness to vaccinate by COVID-19 beliefs and race**

Shown are Odds Ratios (95% CI) for willingness to vaccinate for the survey by race: White (A), Asian (B), and Black (C). Odds Ratios were calculated using ordered logistic regression model with the 4 levels of willingness to be vaccinated as the outcome while adjusting for gender and race. Reference for each survey question is the option ‘neutral’ and is indicated by an open circle. *na* indicates insufficient subjects for this category.


**A.**



**B.**



C.



### S5: Willingness to be vaccinated by Model features from survey

Question	Answer	Women		Men	
		Willing to be Vaccinated			
		No (n=414)	Yes (n=3009)	No (n=228)	Yes (n=375)
In your opinion, how important are vaccines in general?	Not important at all	8 (1.9%)	0 (0%)	6 (2.6%)	0 (0%)
	Not very important	26 (6.3%)	8 (0.3%)	17 (7.5%)	9 (0.2%)
	Somewhat important	144 (34.8%)	120 (4.0%)	88 (38.6%)	180 (4.8%)
	Very important	236 (57.0%)	2881 (95.7%)	117 (51.3%)	3562 (95.0%)
In your opinion, how safe are vaccines in general?	Not at all safe	10 (2.4%)	1 (0.0%)	7 (3.1%)	0 (0%)
	Not very safe	37 (8.9%)	9 (0.3%)	21 (9.2%)	8 (0.2%)
	Somewhat safe	219 (52.9%)	526 (17.5%)	123 (53.9%)	575 (15.3%)
	Very safe	148 (35.7%)	2473 (82.2%)	77 (33.8%)	3168 (84.5%)
Once available to the public, how willing would you be to receive a vaccine to protect you against COVID-19?	Not at all willing	134 (32.4%)	-	62 (27.2%)	-
	Not very willing	280 (67.6%)	-	166 (72.8%)	-
	Somewhat willing	-	1134 (37.7%)	-	921 (24.6%)
	Very Willing	-	1875 (62.3%)	-	2830 (75.4%)
COVID-19 is highly contagious.	Disagree	15 (3.6%)	6 (0.2%)	23 (10.1%)	18 (0.5%)
	Neutral	75 (18.1%)	119 (4.0%)	53 (23.2%)	209 (5.6%)
	Agree	324 (78.3%)	2884 (95.8%)	152 (66.7%)	3524 (93.9%)
COVID-19 is highly severe.	Disagree	50 (12.1%)	75 (2.5%)	52 (22.8%)	135 (3.6%)
	Neutral	118 (28.5%)	501 (16.7%)	60 (26.3%)	716 (19.1%)
	Agree	246 (59.4%)	2433 (80.9%)	116 (50.9%)	2900 (77.3%)
I believe I am at risk of getting COVID-19.	Disagree	77 (18.6%)	143 (4.8%)	48 (21.1%)	137 (3.7%)
	Neutral	140 (33.8%)	733 (24.4%)	76 (33.3%)	826 (22.0%)
	Agree	197 (47.6%)	2133 (70.9%)	104 (45.6%)	2788 (74.3%)
Once approved, I believe a COVID-19 vaccine would be safe and effective.	Disagree	129 (31.2%)	10 (0.3%)	69 (30.3%)	9 (0.2%)
	Neutral	270 (65.2%)	815 (27.1%)	144 (63.2%)	696 (18.6%)
	Agree	15 (3.6%)	2184 (72.6%)	15 (6.6%)	3046 (81.2%)
Once approved, I believe a COVID-19 vaccine will help protect myself and others.	Disagree	80 (19.3%)	1 (0.0%)	53 (23.2%)	2 (0.1%)
	Neutral	304 (73.4%)	473 (15.7%)	153 (67.1%)	388 (10.3%)
	Agree	30 (7.2%)	2535 (84.2%)	22 (9.6%)	3361 (89.6%)
I need more information about a COVID-19 vaccine's safety and efficacy.	Disagree	21 (5.1%)	162 (5.4%)	8 (3.5%)	356 (9.5%)
	Neutral	27 (6.5%)	441 (14.7%)	24 (10.5%)	773 (20.6%)
	Agree	366 (88.4%)	2406 (80.0%)	196 (86.0%)	2622 (69.9%)
I am concerned a COVID-19 vaccine will have side effects.	Disagree	4 (1.0%)	291 (9.7%)	2 (0.9%)	589 (15.7%)
	Neutral	52 (12.6%)	1517 (50.4%)	50 (21.9%)	2127 (56.7%)
	Agree	358 (86.5%)	1201 (39.9%)	176 (77.2%)	1035 (27.6%)
I am concerned my insurance will not cover a COVID-19 vaccine.	Disagree	201 (48.6%)	1540 (51.2%)	122 (53.5%)	2177 (58.0%)
	Neutral	147 (35.5%)	900 (29.9%)	82 (36.0%)	1115 (29.7%)
	Agree	66 (15.9%)	569 (18.9%)	24 (10.5%)	459 (12.2%)
I am concerned about receiving a COVID-19 vaccine because I am afraid of needles	Disagree	366 (88.4%)	2842 (94.4%)	201 (88.2%)	3542 (94.4%)
	Neutral	27 (6.5%)	122 (4.1%)	19 (8.3%)	157 (4.2%)
	Agree	21 (5.1%)	45 (1.5%)	8 (3.5%)	52 (1.4%)
I am comfortable taking a COVID-19 vaccine that has short term side effects such as prolonged injection site pain (e.g., redness or swelling) if the vaccine efficiently prevents COVID-19.	Disagree	123 (29.7%)	20 (0.7%)	65 (28.5%)	19 (0.5%)
	Neutral	113 (27.3%)	139 (4.6%)	78 (34.2%)	210 (5.6%)
	Agree	178 (43.0%)	2850 (94.7%)	85 (37.3%)	3522 (93.9%)
I am comfortable taking a COVID-19 vaccine that has short term side effects such as moderate fever (>38 degrees celsius or > 100 degrees Fahrenheit) if the vaccine efficiently prevents COVID-19.	Disagree	162 (39.1%)	96 (3.2%)	89 (39.0%)	101 (2.7%)
	Neutral	138 (33.3%)	415 (13.8%)	74 (32.5%)	486 (13.0%)
	Agree	114 (27.5%)	2498 (83.0%)	65 (28.5%)	3164 (84.4%)
I am comfortable taking a COVID-19 vaccine that has short term side effects such as stomach pain or nausea if the vaccine efficiently prevents COVID-19.	Disagree	240 (58.0%)	430 (14.3%)	119 (52.2%)	318 (8.5%)
	Neutral	122 (29.5%)	847 (28.1%)	66 (28.9%)	894 (23.8%)
	Agree	52 (12.6%)	1732 (57.6%)	43 (18.9%)	2539 (67.7%)
I would talk to my healthcare provider when considering a COVID-19 vaccine, before deciding whether or not to receive the vaccine.		283 (68.4%)	2750 (91.4%)	142 (62.3%)	3335 (88.9%)
I would talk to none of the above when considering a COVID-19 vaccine, before deciding whether or not to receive the vaccine.		70 (16.9%)	100 (3.3%)	45 (19.7%)	200 (5.3%)
I would do online searches (Google, the vaccine manufacturers website, etc) to help me decide whether or not to receive a COVID-19 vaccine.		177 (42.8%)	1467 (48.8%)	83 (36.4%)	1845 (49.2%)
I would not look for information to help me decide whether or not to receive a COVID-19 vaccine		71 (17.1%)	76 (2.5%)	44 (19.3%)	128 (3.4%)

**Table S6: Impact of positive vaccine efficacy news by level of willing to vaccinate**  
 November 9, 2020, Pfizer announced a first interim analysis reporting >90% efficacy of their vaccine candidate. The impact of this news on willingness was evaluated among those who answered the survey before the 9th to those who answered thereafter (excluding those who answered on the 9th itself). Those after November 9th were more willing to vaccinate (odds ratio 1.46, 95%CI 1.28 – 1.69).

Gender	Time period	Not at all willing	Not very willing	Somewhat willing	Very Willing	Total
Women	Before November 9 <sup>th</sup>	109 (4.2%)	224 (8.6%)	902 (34.5%)	1377 (52.7%)	2612
	After November 9th	14 (2.5%)	46 (8.2%)	162 (28.9%)	339 (60.4%)	561
Men	Before November 9 <sup>th</sup>	51 (1.7%)	136 (4.4%)	757 (24.7%)	2116 (69.2%)	3060
	After November 9th	7 (1.1%)	23 (3.5%)	110 (16.9%)	509 (78.4%)	649
Overall	Before November 9 <sup>th</sup>	160 (2.8%)	360 (6.3%)	1659 (29.2%)	3493 (61.6%)	5672
	After November 9th	21 (1.7%)	69 (5.7%)	272 (22.5%)	848 (70.1%)	1210